☆ 4.7 Article

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Related references

Note: Only part of the references are listed.
Review Urology & Nephrology

Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis

Zhenjie Wu et al.

Summary: This study comprehensively investigated the incidence and profile of adverse events associated with immune checkpoint inhibitor therapy in urologic cancer patients. The findings revealed variations in the spectrum and incidence of adverse events across different cancer types, immune checkpoint inhibitor types, clinical settings, and therapy combinations.

EUROPEAN UROLOGY (2022)

Add to Collection
Article Gastroenterology & Hepatology

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Makoto Chuma et al.

Summary: In patients with unresectable hepatocellular carcinoma, ATZ + BV treatment may offer significant benefits in those who meet IMbrave150 criteria or have low NLR.

HEPATOLOGY RESEARCH (2022)

Add to Collection
Article Biotechnology & Applied Microbiology

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Diego Chowell et al.

Summary: A machine learning model integrating genomic, molecular, demographic, and clinical data accurately predicts clinical response to immune checkpoint blockade in cancer patients. The model outperformed predictions based on tumor mutational burden and provides quantitative assessments of key model features. This approach is expected to substantially improve clinical decision-making in immunotherapy and inform future interventions.

NATURE BIOTECHNOLOGY (2022)

Add to Collection
Review Pharmacology & Pharmacy

Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment

Lucia Lisi et al.

Summary: Immune checkpoint inhibitors have been investigated as an important approach for cancer immunotherapy, but combination therapy may lead to increased immune-related adverse events. The recent development of anti-CTLA-4 probodies and bispecific molecules targeting both CTLA-4 and PD-1 is considered a potential solution to overcome this drawback.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection
Article Pharmacology & Pharmacy

Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system

Chen Chen et al.

Summary: This study compared immune-related adverse events (irAEs) between females and males receiving immune checkpoint inhibitor (ICI) therapy, finding that males had a higher likelihood of developing ICI-associated renal toxicity, longer onset time, and worse prognosis of irAEs compared to females.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2022)

Add to Collection
Review Pharmacology & Pharmacy

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis

Ze Xiang et al.

Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection
Article Oncology

Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database

J. U. N. Y. A. SATO et al.

Summary: This study used the Japanese Adverse Drug Event Report (JADER) database to assess the incidence and timing of durvalumab-induced lung toxicity. The results showed that pneumonia, interstitial lung disease, and radiation-associated pneumonitis were the most common adverse events associated with Durvalumab and had a strong causal relationship. These lung toxicities often occurred approximately 30 days after treatment initiation.

ANTICANCER RESEARCH (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy

Adrienne M. Luoma et al.

Summary: Neoadjuvant immune checkpoint blockade has promising clinical activity in oral cancer patients, inducing both local and systemic tumor immunity. During treatment, tumor-infiltrating CD8 T cells show elevated tissue-resident memory and cytotoxicity programs, and treatment also induces a systemic immune response.

CELL (2022)

Add to Collection
Review Medicine, General & Internal

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences

Ana Cardena-Gutierrez et al.

Summary: ICIs have revolutionized oncology by prolonging overall survival and improving patient tolerance. However, questions remain about the toxicity profile of ICIs and the underlying reasons for different treatment responses. Research has focused on identifying biomarkers to predict treatment response and toxicity, and investigating whether early treatment may affect the long-lasting anti-tumor effect of the immune system.

FRONTIERS IN MEDICINE (2022)

Add to Collection
Article Multidisciplinary Sciences

On maternity and the stronger immune response in women

Evan Mitchell et al.

Summary: Women generally exhibit stronger immune responses and pathogens tend to be more virulent in men, which current explanations cannot account for. This study proposes an alternative explanation based on the transmission of pathogens from mother to child, using a mathematical model of the co-evolution of host immunocompetence and pathogen virulence.

NATURE COMMUNICATIONS (2022)

Add to Collection
Review Oncology

Immune Checkpoint Inhibitors in Cancer Therapy

Yavar Shiravand et al.

Summary: The discovery of immune checkpoint proteins has revolutionized cancer immunotherapy, leading to the successful utilization of targeted monoclonal antibodies in various cancer patients. However, not all patients respond favorably to these drugs, emphasizing the need for biomarkers to predict treatment responses.

CURRENT ONCOLOGY (2022)

Add to Collection
Review Immunology

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors

Adithya Chennamadhavuni et al.

Summary: This review provides a practical list of risk factors and biomarkers to consider when initiating or monitoring immune-checkpoint inhibitor (ICI) therapy. It emphasizes the importance of personalized risk assessment for immune-related adverse events (irAEs) and the need for further studies to gain insight into this essential aspect of ICI therapy.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Oncology

Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer

Nilay Sengul Samanci et al.

Summary: The study investigated 255 patients treated with immune checkpoint inhibitors, finding that 27.8% of patients experienced immune-related adverse events, with pneumonitis, hepatitis, and hypothyroidism being the most common manifestations. Additionally, 42% of adverse events occurred after anti-PD-1 therapy.

TUMORI JOURNAL (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Golnaz Morad et al.

Summary: This passage discusses the unprecedented advances in cancer treatment with immune checkpoint blockade (ICB), highlighting the critical need for insights into factors intrinsic and extrinsic to the host that impact ICB response and toxicity. There has been substantial progress in understanding the impact of host-intrinsic factors and the exposome on host physiology and response to treatment, representing the hallmarks of response, resistance, and toxicity to ICB in current day.

CELL (2021)

Add to Collection
Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection
Article Oncology

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Alice Baggi et al.

Summary: A retrospective observational study in Italy evaluated the clinical outcomes of patients with advanced cSCC treated with cemiplimab. The study showed comparable safety and effectiveness results to clinical trials, and identified some clinical and biochemical factors potentially associated with response to cemiplimab.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection
Article Oncology

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

D. R. Spigel et al.

Summary: Nivolumab did not show survival benefit compared to chemotherapy in relapsed SCLC, but there is a potential survival benefit in certain baseline characteristics.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Review Medicine, Research & Experimental

Immune checkpoint inhibitor-associated myocarditis: manifestations arms mechanisms

Javid Moslehi et al.

Summary: Immune checkpoint inhibitors have revolutionized the treatment of cancer, but associated toxicities like myocarditis pose challenges that require further research, predictive biomarker identification, and improved diagnostic and treatment strategies.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection
Article Oncology

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Ying Jing et al.

Summary: Analysis of clinical study data, pharmacovigilance data, and genomic data revealed minimal sex-associated differences in immune-related adverse events (irAEs) among cancer patients treated with immune checkpoint inhibitors. Therefore, considering sex effects for irAE management in clinical practice may be unnecessary.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection
Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

Add to Collection
Review Immunology

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

Jee Hye Kang et al.

Summary: Cancer immunotherapies can activate immune responses against tumors but may also lead to immune-related adverse events, with cytokine production playing a key role. Therapeutic agents that inhibit cytokine activity can reduce the severity of these adverse events.

TRENDS IN IMMUNOLOGY (2021)

Add to Collection
Review Oncology

Considerations for treatment duration in responders to immune checkpoint inhibitors

Thomas U. Marron et al.

Summary: Although immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, the optimal duration of therapy remains undefined and further research is needed. Early trials have shown that a significant percentage of patients have durable responses to ICIs, prompting the question of whether patients may be receiving too much treatment and if durable remissions can still be achieved with shorter courses. Designing well-controlled trials to identify biomarkers for predicting patients who would benefit from shorter courses of immunotherapy is crucial for future work in this area.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Immunology

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy

Selina K. Wong et al.

Summary: The addition of immune checkpoint inhibitors (ICIs) to cancer treatment has greatly improved patient outcomes, but there is significant variability in responses to these drugs among different individuals, leading to different treatment outcomes.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer A Multicenter International Cohort Study

Caroline A. Nebhan et al.

Summary: An international multicenter retrospective study showed that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, although ICI discontinuation due to irAEs was more frequent with increasing age.

JAMA ONCOLOGY (2021)

Add to Collection
Article Medicine, General & Internal

Immune-related adverse events with immune checkpoint inhibitors Special reference to the effects on the lungs

Aya Hirata et al.

Summary: This study revealed that lung-irAEs have a longer onset period compared to other major organs, and can have a positive impact on both progression-free survival (PFS) and overall survival (OS). However, the positive effect of lung-irAEs does not seem to be proportional to the severity, and may not necessarily prolong OS and PFS. Further research is needed to confirm these findings.

MEDICINE (2021)

Add to Collection
Review Endocrinology & Metabolism

Endocrine toxicities of immune checkpoint inhibitors

Jordan J. Wright et al.

Summary: Immune checkpoint inhibitors (ICIs) have become a cornerstone of cancer therapeutics, but can also cause toxicities in various organs known as immune-related adverse events. ICIs can lead to endocrinopathies involving the thyroid, pituitary, adrenal glands, and pancreas, which are common and sometimes fatal.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection
Article Oncology

Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma

Julie Valentin et al.

Summary: In this study, 22 patients with a median age of 83 [55-93] were evaluated for the safety of cemiplimab in daily practice. 77% of patients experienced 24 adverse events, with 45% being serious adverse events (SAEs) grade >= 3. One patient had a SAE grade 5 (myositis). 41% of patients discontinued treatment definitively due to adverse events. After a median follow-up of eleven months [1-22], 32% had an objective response, 47% had controlled disease, and 35% experienced progression. The safety profile observed in this cohort was worse than in phase II trials, with more treatment discontinuations due to cemiplimab toxicity.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

Add to Collection
Article Oncology

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma

J. Randall Patrinely et al.

Summary: This multicenter cohort study found that chronic immune-related adverse events (irAEs) associated with anti-PD-1 therapy were more common than previously recognized, with a considerable proportion of patients developing chronic irAEs such as endocrinopathies and arthritis. Visceral organ-related irAEs had lower rates of becoming chronic, highlighting the importance of considering the risks of chronic irAEs in treatment decision-making.

JAMA ONCOLOGY (2021)

Add to Collection
Article Oncology

Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy

Xinyi Huang et al.

Summary: This study compared the occurrence of immune-related adverse events (irAEs) in different age groups receiving immune checkpoint inhibition therapy. It was found that older patients had higher incidences of pulmonary toxicity and lower rates of hepatitis compared to younger patients. Additionally, older patients showed decreased infiltration of B cells, CD8(+) T cells, and myeloid dendritic cells.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Review Oncology

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Hao Zhang et al.

Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Kerry L. Reynolds et al.

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but immune-related adverse events (irAEs) can be serious in some patients. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Oncology

Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis

Zhe Zhao et al.

Summary: Immune-related adverse events induced by anti-PD-1 antibodies are strongly correlated with improved clinical outcomes in patients with non-small cell lung cancer, suggesting their potential as predictive biomarkers for treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Correction Oncology

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors (vol 9, e002890, 2021)

A. C. Guidon et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence

Ying Xu et al.

Summary: Immunotherapies play critical roles in cancer treatment, but the response rate is low, requiring more novel technologies to study the tumor immune microenvironment. Tumor immunomics integrates various omics data to study TIME and predict tumor immune states, relied on next-generation sequencing for rapid development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection
Editorial Material Biotechnology & Applied Microbiology

Trends in clinical development for PD-1/PD-L1 inhibitors

Jia Xin Yu et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection
Article Oncology

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Sex-associated molecular differences for cancer immunotherapy

Youqiong Ye et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Article Medicine, General & Internal

Immune-related adverse events of checkpoint inhibitors

Manuel Ramos-Casals et al.

NATURE REVIEWS DISEASE PRIMERS (2020)

Add to Collection
Article Oncology

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

Douglas B Johnson et al.

LANCET ONCOLOGY (2020)

Add to Collection
Review Oncology

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

Xiao-Hui Jia et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

Add to Collection
Review Immunology

Does patient age influence anti-cancer immunity?

Graham Pawelec

SEMINARS IN IMMUNOPATHOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

Add to Collection
Review Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis

Yucai Wang et al.

JAMA ONCOLOGY (2019)

Add to Collection
Editorial Material Genetics & Heredity

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach

Zia Khan et al.

GENOME MEDICINE (2019)

Add to Collection
Article Oncology

Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma

Eva Kassi et al.

CANCER MEDICINE (2019)

Add to Collection
Article Oncology

Durvalumab for the treatment of non-small cell lung cancer

Shuji Murakami

EXPERT REVIEW OF ANTICANCER THERAPY (2019)

Add to Collection
Article Immunology

Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab

Chanakyaram A. Reddy et al.

IMMUNOTHERAPY (2019)

Add to Collection
Article Oncology

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma

Marco Tucci et al.

ONCOIMMUNOLOGY (2018)

Add to Collection
Article Oncology

Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials

Karen Kelly et al.

CANCER (2018)

Add to Collection
Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Review Oncology

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Xiaolei Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Oncology

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

Add to Collection
Editorial Material Biotechnology & Applied Microbiology

The global landscape of cancer cell therapy

Jun Tang et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Add to Collection
Review Immunology

The Confluence of Sex Hormones and Aging on Immunity

Melanie R. Gubbels Bupp et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Oncology

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Alexander N. Shoushtari et al.

JAMA ONCOLOGY (2018)

Add to Collection
Article Oncology

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer

Koji Haratani et al.

JAMA ONCOLOGY (2018)

Add to Collection
Article Oncology

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Y. Dirix et al.

BREAST CANCER RESEARCH AND TREATMENT (2018)

Add to Collection
Article Oncology

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

David Y. Oh et al.

CANCER RESEARCH (2017)

Add to Collection
Article Oncology

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Shunsuke Teraoka et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection
Article Oncology

Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors

Julia Judd et al.

ONCOLOGIST (2017)

Add to Collection
Article Oncology

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Morganna Freeman-Keller et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Review Immunology

Sex differences in immune responses

Sabra L. Klein et al.

NATURE REVIEWS IMMUNOLOGY (2016)

Add to Collection
Article Medicine, General & Internal

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Anne Bertrand et al.

BMC MEDICINE (2015)

Add to Collection
Review Cell Biology

Sex, the aging immune system, and chronic disease

Melanie R. Gubbels Bupp

CELLULAR IMMUNOLOGY (2015)

Add to Collection
Review Oncology

Toxicities of Immunotherapy for the Practitioner

Jeffrey S. Weber et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection
Review Geriatrics & Gerontology

The neuroendocrine physiology of female reproductive aging: An update

Genevieve Neal-Perry et al.

MATURITAS (2010)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.